PT1698640E - Processo para estabilizar um anticorpo e composição sob a forma de solução estabilizada contendo o anticorpo - Google Patents

Processo para estabilizar um anticorpo e composição sob a forma de solução estabilizada contendo o anticorpo Download PDF

Info

Publication number
PT1698640E
PT1698640E PT47737002T PT04773700T PT1698640E PT 1698640 E PT1698640 E PT 1698640E PT 47737002 T PT47737002 T PT 47737002T PT 04773700 T PT04773700 T PT 04773700T PT 1698640 E PT1698640 E PT 1698640E
Authority
PT
Portugal
Prior art keywords
antibody
stabilizing
stabilized solution
type
preparation
Prior art date
Application number
PT47737002T
Other languages
English (en)
Inventor
Ueno Yuji
Kayashita Takashi
Ishihara Atsushi
Yamauchi Kyoko
Nakakura Masashi
Original Assignee
Kyowa Hakko Kirin Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34419308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1698640(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyowa Hakko Kirin Co Ltd filed Critical Kyowa Hakko Kirin Co Ltd
Publication of PT1698640E publication Critical patent/PT1698640E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
PT47737002T 2003-10-01 2004-10-01 Processo para estabilizar um anticorpo e composição sob a forma de solução estabilizada contendo o anticorpo PT1698640E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2003343645 2003-10-01

Publications (1)

Publication Number Publication Date
PT1698640E true PT1698640E (pt) 2016-03-31

Family

ID=34419308

Family Applications (1)

Application Number Title Priority Date Filing Date
PT47737002T PT1698640E (pt) 2003-10-01 2004-10-01 Processo para estabilizar um anticorpo e composição sob a forma de solução estabilizada contendo o anticorpo

Country Status (16)

Country Link
US (3) US8496930B2 (pt)
EP (2) EP3006463A1 (pt)
JP (1) JP4219932B2 (pt)
KR (1) KR100911091B1 (pt)
CN (1) CN100522998C (pt)
AU (1) AU2004277466C1 (pt)
CA (1) CA2540848C (pt)
CY (1) CY1117215T1 (pt)
DK (1) DK1698640T4 (pt)
ES (1) ES2562912T5 (pt)
HK (1) HK1090933A1 (pt)
HU (1) HUE026793T2 (pt)
PL (1) PL1698640T5 (pt)
PT (1) PT1698640E (pt)
SI (1) SI1698640T2 (pt)
WO (1) WO2005033143A1 (pt)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7883704B2 (en) * 1999-03-25 2011-02-08 Abbott Gmbh & Co. Kg Methods for inhibiting the activity of the P40 subunit of human IL-12
US6914128B1 (en) * 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
WO2005033143A1 (ja) * 2003-10-01 2005-04-14 Kyowa Hakko Kogyo Co., Ltd. 抗体の安定化方法及び安定化された溶液状抗体製剤
WO2006125207A2 (en) * 2005-05-19 2006-11-23 Amgen Inc. Compositions and methods for increasing the stability of antibodies
US20070190047A1 (en) * 2005-07-29 2007-08-16 Amgen, Inc. Formulations that inhibit protein aggregation
MEP39508A (en) * 2006-04-21 2011-02-10 Novartis Ag Antagonist anti-cd40 antibody pharmaceutical compositions
AU2007234612B2 (en) 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
MX2009007570A (es) * 2007-01-16 2009-07-22 Abbott Lab Metodos para tratar la psoriasis.
MX2009010361A (es) 2007-03-29 2009-10-16 Abbott Lab Anticuerpos il-12 anti-humanos cristalinos.
WO2009073569A2 (en) * 2007-11-30 2009-06-11 Abbott Laboratories Protein formulations and methods of making same
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
TWI461210B (zh) * 2008-03-18 2014-11-21 Abbvie Inc 治療牛皮癬的方法
WO2010062896A1 (en) * 2008-11-28 2010-06-03 Abbott Laboratories Stable antibody compositions and methods for stabilizing same
NZ613809A (en) * 2009-05-04 2015-02-27 Abbvie Biotechnology Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
PT2437781E (pt) 2009-06-04 2013-10-30 Alk Ag Composição estabilizada que compreende pelo menos um composto adrenérgico
KR20120112384A (ko) * 2009-09-14 2012-10-11 애보트 게엠베하 운트 콤파니 카게 건선을 치료하는 방법
AU2011219715B2 (en) 2010-02-26 2014-12-11 Novo Nordisk A/S Stable antibody containing compositions
MX2012010198A (es) 2010-03-01 2012-10-03 Bayer Healthcare Llc Anticuerpos monoclonales optimizados contra el inhibidor de la via del factor tisular (tfpi).
CN102905692B (zh) 2010-05-28 2015-09-16 诺沃—诺迪斯克有限公司 包含抗体和防腐剂的稳定的多剂量组合物
EA027353B1 (ru) 2010-09-17 2017-07-31 Баксалта Инкорпорейтид СТАБИЛИЗАЦИЯ ИММУНОГЛОБУЛИНОВ С ПОМОЩЬЮ ВОДНОГО СОСТАВА С ГИСТИДИНОМ ПРИ pH ОТ СЛАБОКИСЛОГО ДО НЕЙТРАЛЬНОГО
CN103458926B (zh) 2010-11-11 2016-10-26 艾伯维生物技术有限公司 改进的高浓度抗TNF α 抗体液体制剂
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
EP2949336B1 (en) 2013-01-28 2018-09-05 National University Corporation Kumamoto University Stabilized protein gel preparation
AU2014291970B2 (en) * 2013-07-19 2017-09-28 Hexal Ag Methods and formulations which allow the modulation of immune responses related to the administration of a biopharmaceutical drug
CN103772505B (zh) * 2013-12-18 2014-10-15 长春博迅生物技术有限责任公司 一种抗体试剂保存液
EP3374390A1 (en) 2015-11-13 2018-09-19 Visterra, Inc. Compositions and methods for treating and preventing influenza
CA3015347A1 (en) * 2016-02-24 2017-08-31 Visterra, Inc. Formulations of antibody molecules to influenza virus
WO2017170626A1 (ja) * 2016-03-30 2017-10-05 千寿製薬株式会社 水性液剤
BR112021015034A2 (pt) 2019-02-18 2021-10-05 Eli Lilly And Company Formulação de anticorpo terapêutico
EP3946613A1 (en) 2019-03-25 2022-02-09 Visterra, Inc. Compositions and methods for treating and preventing influenza
WO2021070203A1 (en) * 2019-10-11 2021-04-15 Dr. Reddy's Laboratories Limited Stable formulation of integrin antibody

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US421777A (en) * 1890-02-18 Straining-pot
JPH0669961B2 (ja) * 1984-09-25 1994-09-07 株式会社ミドリ十字 免疫グロブリンの加熱処理方法
US4597966A (en) 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
JPS62194459A (ja) * 1986-02-21 1987-08-26 Sankyo Co Ltd 固相化試薬の安定化剤
JPS62244441A (ja) 1986-04-16 1987-10-24 Green Cross Corp:The 抗体固定化担体
DE3734923C1 (de) * 1987-10-15 1989-01-26 Biotest Pharma Gmbh Verfahren zur Herstellung einer sterilen Plasmaproteinloesung,die Fibrinogen und den Gerinnungsfaktor XIII enthaelt
JPH03504499A (ja) 1988-05-27 1991-10-03 セントカー・インコーポレーテツド 抗体試薬のための配合物
US5945098A (en) 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
JP2966592B2 (ja) 1991-07-20 1999-10-25 萩原 義秀 安定化されたヒトモノクローナル抗体製剤
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
GB9122820D0 (en) * 1991-10-28 1991-12-11 Wellcome Found Stabilised antibodies
JP3368282B2 (ja) 1992-04-30 2003-01-20 ミレニアム ファーマシューティカルズ，インコーポレイティド 安定なポリペプチド組成物
JPH06189781A (ja) 1992-12-25 1994-07-12 Mitsui Toatsu Chem Inc 培養液中の生理活性タンパク質の安定化方法
FR2708467B1 (fr) 1993-07-30 1995-10-20 Pasteur Merieux Serums Vacc Préparations d'immunoglobulines stabilisées et procédé pour leur préparation.
GB9418092D0 (en) 1994-09-08 1994-10-26 Red Cross Found Cent Lab Blood Organic compounds
MX9706827A (es) * 1995-03-10 1997-11-29 Genentech Inc Activacion de receptor por gas6.
AU2444899A (en) * 1998-01-22 1999-08-09 Astrazeneca Ab Pharmaceutical formulation comprising an antibody and a citrate buffer
US6488930B1 (en) * 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
EP1174148A4 (en) 1999-04-28 2005-05-04 Yamanouchi Pharma Co Ltd PARENTAL MEDICAL COMPOSITIONS CONTAINING FRAGMENTS OF HUMANIZED MONOCLONAL ANTIBODIES AND METHOD FOR STABILIZING THE SAME
EP1050307A1 (en) * 1999-05-06 2000-11-08 Applied Research Systems ARS Holding N.V. CCR4 antagonists in sepsis
IL147017A0 (en) 1999-06-25 2002-08-14 Genentech Inc TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES
EP1238985B1 (en) 1999-09-30 2008-03-05 Kyowa Hakko Kogyo Co., Ltd. Human type complementarity determining region transplantation antibody against ganglioside gd3 and derivatives of antibody against ganglioside gd3
JP4516711B2 (ja) * 1999-12-28 2010-08-04 中外製薬株式会社 安定な抗体組成物及び注射製剤
DE60134962D1 (de) 2000-03-03 2008-09-04 Kyowa Hakko Kogyo Kk Anti-ccr4 antikörper und fragmente davon
ES2477996T3 (es) * 2000-08-11 2014-07-18 Chugai Seiyaku Kabushiki Kaisha Preparaciones estabilizadas que contienen un anticuerpo
EP1449850B9 (en) 2001-08-31 2011-05-11 Kyowa Hakko Kirin Co., Ltd. Human cdr-grafted antibodies and antibody fragments thereof
CA2466025A1 (en) 2001-11-02 2003-08-07 Centocor, Inc. Rsv proteins, antibodies, compositions, methods and uses
DK1475101T3 (da) 2002-02-14 2011-01-10 Chugai Pharmaceutical Co Ltd Antistof-holdige farmaceutiske opløsninger
WO2005033143A1 (ja) * 2003-10-01 2005-04-14 Kyowa Hakko Kogyo Co., Ltd. 抗体の安定化方法及び安定化された溶液状抗体製剤

Also Published As

Publication number Publication date
SI1698640T2 (sl) 2019-08-30
PL1698640T3 (pl) 2016-05-31
JP4219932B2 (ja) 2009-02-04
KR100911091B1 (ko) 2009-08-06
CN1856507A (zh) 2006-11-01
PL1698640T5 (pl) 2019-12-31
AU2004277466C1 (en) 2022-06-23
EP1698640B2 (en) 2019-06-19
US20130280248A1 (en) 2013-10-24
EP1698640A1 (en) 2006-09-06
WO2005033143A1 (ja) 2005-04-14
EP3006463A1 (en) 2016-04-13
US9011850B2 (en) 2015-04-21
US8496930B2 (en) 2013-07-30
SI1698640T1 (sl) 2016-03-31
CY1117215T1 (el) 2017-04-05
AU2004277466B2 (en) 2010-04-01
CA2540848C (en) 2012-12-11
US20150190507A1 (en) 2015-07-09
DK1698640T3 (en) 2016-02-15
US20070020255A1 (en) 2007-01-25
US10172790B2 (en) 2019-01-08
EP1698640A4 (en) 2008-09-17
DK1698640T4 (da) 2019-09-02
KR20060089227A (ko) 2006-08-08
AU2004277466A1 (en) 2005-04-14
EP1698640B1 (en) 2015-12-30
ES2562912T3 (es) 2016-03-09
JPWO2005033143A1 (ja) 2007-11-15
CN100522998C (zh) 2009-08-05
ES2562912T5 (es) 2020-02-18
HUE026793T2 (en) 2016-07-28
CA2540848A1 (en) 2005-04-14
HK1090933A1 (zh) 2007-01-05

Similar Documents

Publication Publication Date Title
HK1090933A1 (zh) 穩定抗體的方法及穩定化溶液狀抗體製劑
TWI367766B (en) Immunoglobulin formulation and method of preparation thereof
HUE038498T2 (hu) Immunglobulin készítmény és elõállítási módszere
EP1482984A4 (en) REPLACEMENT ANTIBODIES AND METHOD FOR THEIR MANUFACTURE AND USE
ZA200305825B (en) Modified antibodies and methods of use
ZA200506790B (en) Arylvinylazacycloalkane compounds and method of preparation and use thereof
EP1464702A4 (en) METHOD FOR PROTEIN STABILIZATION
IL172689A0 (en) Pro104 ANTIBODY COMPOSITIONS AND METHODS OF USE
AU2003265522A1 (en) FCGammaRIIB-SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
EP1648316A4 (en) VERTEBRAL RETENTION AND CLEARANCE DEVICE AND METHOD OF USE
AU2003277259A8 (en) Immunoassay and method of use
IL175657A0 (en) Derivatives of dihydronepetalactone and method for preparation
GB2414287B (en) Peltier based freeze-thaw valves and method of use
EP1541165A4 (en) METHOD FOR STABILIZING PROTEIN PREPARATION
EP1686137A4 (en) PROCESS FOR STABILIZING PROTEIN SOLUTIONS
AU2003276844A8 (en) Formulations of modified antibodies and methods of making the same
PL1667624T3 (pl) Układ zamknięcia i sposób wytwarzania
EP1633850A4 (en) OVR115 ANTIBODY COMPOSITIONS AND METHODS OF USE
GB0304555D0 (en) Compounds and methods of manufacture
EP1680489A4 (en) EMULSION FUEL AND PROCESS FOR PREPARING THE SAME
EP1686990A4 (en) 2-GUANIDINYLIMIDAZOLIDINEDIONE COMPOUNDS: METHODS OF PREPARATION AND USE
EP1549951A4 (en) SEMAPHORIN-LIKE PROTEINS AND METHODS OF USE THEREOF
EP1616020A4 (en) ANTI-CR1 ANTIBODIES WITH REDUCED IMMUNOGENICITY AND COMPOSITIONS AND TREATMENT METHODS BASED ON THEM
PL356624A1 (en) Flavoured vodka and method of its preparation
PL356684A1 (en) Method of receiving dietetic-therapeutic preparations and their application